Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
NextCure (Nasdaq: NXTC) reported Q1 2026 results and a business update on May 7, 2026. Key clinical progress: FDA Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, Phase 1 dose-escalation data to be presented at ASCO 2026 on June 1, 2026, and initiation of a dose-optimization study. Cash totaled $29.7M at March 31, 2026, with runway expected into the first half of 2027 through SIM0505 proof-of-concept.
NextCure (Nasdaq: NXTC) and Simcere Zaiming initiated the dose optimization portion of the Phase 1 study of SIM0505, an investigational CDH6-targeting ADC, focused initially on patients with platinum-resistant ovarian cancer (PROC).
The program will expand U.S. and China trial sites and add sites in Canada and Europe. Phase 1 data readout is planned for ASCO 2026.
NextCure (Nasdaq: NXTC) and Simcere will present Phase 1 data for SIM0505, an anti-CDH6 antibody-drug-conjugate (ADC), as a poster at ASCO 2026.
The poster (Abstract #5580, Board 246) will be presented June 1, 2026, by Xiaohua Wu, MD, PhD; the poster will be posted on the company investor site after the session.
NextCure (Nasdaq: NXTC) announced the FDA granted Fast Track designation to SIM0505, an anti-CDH6 antibody-drug conjugate, for treatment of platinum-resistant ovarian cancer.
The company plans to begin dose optimization in Q2 2026 and will present Phase 1 data at ASCO 2026, enabling closer FDA engagement to accelerate development.
NextCure (Nasdaq: NXTC) and Simcere announced that an abstract for SIM0505 (CDH6 ADC) was accepted for presentation at ASCO 2026, held May 29–June 2 in Chicago. SIM0505 is an investigational ADC targeting Cadherin-6 (CDH6) with a proprietary TOPOi payload.
The ongoing open-label Phase 1 study (NCT06792552) is evaluating SIM0505 in advanced solid tumors, including ovarian cancer, with emphasis on platinum-resistant ovarian cancer.
NextCure (Nasdaq: NXTC) provided a business update and reported full-year 2025 results on March 5, 2026. Key clinical milestones include SIM0505 Phase 1 dose escalation data expected Q2 2026 and initiation of a Phase 1 dose optimization study in platinum resistant ovarian cancer in Q2 2026. LNCB74 enrollment continues with a trial update planned H2 2026. Financials: $41.8M cash at year-end and net loss of $55.8M for 2025; company expects runway into H1 2027 through SIM0505 proof-of-concept.
NextCure (NASDAQ: NXTC) provided a business update on Jan 23, 2026, reporting clinical progress for two ADC programs and a preliminary year-end cash position.
SIM0505 (CDH6 ADC): Phase 1 dose-escalation data from U.S. and China cohorts are expected in Q2 2026; company is adding sites and increasing drug supply to start dose optimization in H1 2026. LNCB74 (B7-H4 ADC): dose escalation expanded into higher cohorts with prioritization of high B7-H4 breast and gynecological cancer patients; proof-of-concept timing delayed to a trial update in 2H 2026. Financials: preliminary cash and equivalents approx $41.8M, expected to fund operations into 1H 2027.
NextCure (Nasdaq: NXTC) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City on Wednesday, December 3, 2025 at 11:00 AM ET.
A live audio webcast will be available via the company's Investors website and a replay will be archived on the site for 30 days after the event.
NextCure (Nasdaq: NXTC) closed a private placement PIPE on Nov 17, 2025 raising approximately $21.5 million in gross proceeds. The financing sold 708,428 common shares at $8.52 per share and pre-funded warrants to purchase up to 1,815,049 shares at $8.519 each.
Led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management, with H.C. Wainwright as placement agent, the net proceeds are intended for general working capital and to extend the company’s cash runway into H1 2027, beyond planned H1 2026 proof‑of‑concept data readouts for ADC programs SIM0505 (CDH6) and LNCB74 (B7‑H4).
NextCure (Nasdaq:NXTC) announced a private placement to sell an aggregate of 2,523,477 shares of common stock (or pre-funded warrants) at $8.52 per share, priced at-the-market under Nasdaq rules, with expected gross proceeds of approximately $21.5 million. The offering is expected to close on or about November 13, 2025, subject to customary closing conditions, with H.C. Wainwright acting as exclusive placement agent.
The company said it intends to use net proceeds for general working capital, extending its cash runway into the first half of 2027, beyond the previously planned first half of 2026, and to support proof-of-concept data readouts for ADC programs SIM0505 (CDH6) and LNCB74 (B7-H4). The securities are offered under Section 4(a)(2)/Regulation D and will be registered for resale pursuant to a registration rights agreement.